Phenotypes Associated with This Genotype

Genotype
MGI:3053858

• Allelic Composition: Npy1r^tm1.1Wpg/Npy1r^tm1.1Wpg
• Genetic Background: involves: 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:124729 )

• kainic acid-exposed mice over-expressing rAAV1/2-NPY exhibit no mortality unlike similarly treated wild-type mice

reproductive system

increased litter size ( J:92440 )

• average litter size is 7.64 +/- 0.51 compared to 4.86 +/- 0.32 in wild-type mice

immune system

decreased B cell number ( J:118850 )

• all B cell subsets reduced

decreased transitional stage B cell number ( J:118850 )

• type 1 and type 2 cells both reduced

decreased mature B cell number ( J:118850 )

abnormal T cell number ( J:118850 )

increased CD4-positive, alpha-beta T cell number ( J:118850 )

• significantly increased in the lymph nodes

decreased CD8-positive, alpha-beta T cell number ( J:118850 )

• slightly reduced in the spleen

increased CD8-positive, alpha-beta T cell number ( J:118850 )

• significantly increased in the lymph nodes

increased single-positive T cell number ( J:118850 )

abnormal immune system organ morphology ( J:118850 )

abnormal spleen morphology ( J:118850 )

decreased marginal zone B cell number ( J:118850 )

small spleen ( J:118850 )

abnormal splenic cell ratio ( J:118850 )

• reduced B cell numbers among splenocytes

abnormal lymph node cell ratio ( J:118850 )

• reduced numbers of B cells

abnormal immune system physiology ( J:118850 )

decreased circulating interleukin-12 level ( J:118850 )

• decreased levels released by macrophage

decreased circulating tumor necrosis factor level ( J:118850 )

• decreased levels released by macrophage

abnormal immune cell physiology ( J:118850 )

abnormal T-helper 1 physiology ( J:118850 )

• impaired

• protected against Th1 cell mediated inflammatory conditions such as those resulting from sodium dextran sulfate treatment

abnormal T cell activation ( J:118850 )

• hyper responsive to activation

abnormal professional antigen presenting cell physiology ( J:118850 )

• antigen presentation defective as tested by mixed lymphocyte response tests

abnormal immunoglobulin level ( J:118850 )

decreased IgG2a level ( J:118850 )

• both baseline levels and levels in response to antigen are reduced

increased immunoglobulin level ( J:118850 )

• in response to antigen

increased IgA level ( J:118850 )

increased IgG2b level ( J:118850 )

increased IgM level ( J:118850 )

abnormal macrophage physiology ( J:118850 )

• levels of Il12 released are reduced

• levels of TNF released are reduced

decreased interferon-gamma secretion ( J:118850 )

• reduced production

abnormal inflammatory response ( J:118850 )

decreased susceptibility to type IV hypersensitivity reaction ( J:118850 )

• swelling reduced to 55% that of controls

• reduced proliferation of lymph node cells

• reduced production of IFN-gamma

homeostasis/metabolism

decreased circulating interleukin-12 level ( J:118850 )

• decreased levels released by macrophage

decreased circulating tumor necrosis factor level ( J:118850 )

• decreased levels released by macrophage

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:124729 )

• kainic acid-exposed mice over-expressing rAAV1/2-NPY exhibit no mortality unlike similarly treated wild-type mice

behavior/neurological

increased aggression towards mice ( J:92440 )

• territorial aggression but not spontaneous aggression is increased in homozygous mutants

• injection of an Htr1a agonist reduces aggressive behavior in a dose-dependent manner

hyperactivity ( J:92440 )

• homozygous males display increased movement in an open field test

nervous system

abnormal neuron differentiation ( J:92582 )

• in primary cultures proliferation of post-natal hippocampal precursor cells is not increased in response to neuropeptide Y treatment

hematopoietic system

decreased B cell number ( J:118850 )

• all B cell subsets reduced

decreased transitional stage B cell number ( J:118850 )

• type 1 and type 2 cells both reduced

decreased mature B cell number ( J:118850 )

decreased marginal zone B cell number ( J:118850 )

abnormal T cell number ( J:118850 )

increased CD4-positive, alpha-beta T cell number ( J:118850 )

• significantly increased in the lymph nodes

decreased CD8-positive, alpha-beta T cell number ( J:118850 )

• slightly reduced in the spleen

increased CD8-positive, alpha-beta T cell number ( J:118850 )

• significantly increased in the lymph nodes

increased single-positive T cell number ( J:118850 )

abnormal spleen morphology ( J:118850 )

small spleen ( J:118850 )

abnormal splenic cell ratio ( J:118850 )

• reduced B cell numbers among splenocytes

abnormal immunoglobulin level ( J:118850 )

decreased IgG2a level ( J:118850 )

• both baseline levels and levels in response to antigen are reduced

increased immunoglobulin level ( J:118850 )

• in response to antigen

increased IgA level ( J:118850 )

increased IgG2b level ( J:118850 )

increased IgM level ( J:118850 )

abnormal T-helper 1 physiology ( J:118850 )

• impaired

• protected against Th1 cell mediated inflammatory conditions such as those resulting from sodium dextran sulfate treatment

abnormal T cell activation ( J:118850 )

• hyper responsive to activation

abnormal macrophage physiology ( J:118850 )

• levels of Il12 released are reduced

• levels of TNF released are reduced

cellular

abnormal neuron differentiation ( J:92582 )

• in primary cultures proliferation of post-natal hippocampal precursor cells is not increased in response to neuropeptide Y treatment